Advancements in the Treatment of Pediatric EB Virus Infections: A Comparative Analysis of Valaciclovir Hydrochloride and Ganciclovir
Epstein-Barr virus (EBV) infections remain a significant health concern globally, particularly among pediatric populations. Characterized by symptoms such as fever, pharyngitis, lymphadenopathy, and fatigue, EBV can lead to severe complications like infectious mononucleosis and has been linked to long-term conditions including certain cancers and autoimmune disorders. Traditional antiviral therapies, such as intravenous ganciclovir, have been the cornerstone of treatment. However, emerging research highlights the potential of oral valaciclovir hydrochloride as a viable alternative. This article explores recent advancements in the pharmacological optimization of valaciclovir and its clinical efficacy compared to ganciclovir in treating pediatric EBV infections. The Role of Valaciclovir Hydrochloride in Antiviral Therapy Valaciclovir hydrochloride is a prodrug of acyclovir, designed to enhance bioavailability through targeted delivery. Its mechanism of action involves inhibiting viral DN...